VOGX IPO Surges 127% on Mizagliflozin for PBH

Vogenx (VOGX) is the market’s newest way to bet on post-bariatric hypoglycemia (PBH), a condition that causes dangerous blood-sugar crashes after weight-loss surgery. The Raleigh, North Carolina biotech priced its IPO at $13.00 per share, the top of its $11 to $13 range, on August 11 and began trading August 12, raising about $81.3 million. The stock has since run to $29.52, a gain of roughly 127% over the offer price.

The rally is a momentum play on an indication that just got validated by a bigger peer. On August 18, Amylyx Pharmaceuticals reported that avexitide, a GLP-1 receptor antagonist, hit its primary endpoint in the Phase 3 LUCIDITY trial, cutting hypoglycemic events by 55%. Vogenx’s mizagliflozin attacks the same disease through a different mechanism: it is an oral, minimally absorbed SGLT1 inhibitor that blunts glucose absorption in the gut, reducing the insulin surge that drives post-meal hypoglycemia. SGLT1 is the transporter that moves glucose from the intestines into the bloodstream, and in PBH patients it is overexpressed, so blocking it slows the glucose spike that triggers the body’s overcorrection.

The company licensed mizagliflozin from Kissei Pharmaceutical in 2021, taking worldwide rights outside Japan, Korea, and Taiwan. In earlier Phase 2 studies in PBH patients, the drug reduced Level 3 hypoglycemia by 67% at the 5 mg dose and Level 2 hypoglycemia by 76% at 10 mg. The company plans to spend $26.3 million to advance mizagliflozin through the Phase 2b EMERGE study, with preliminary results expected in 2027. Vogenx estimates PBH affects more than 450,000 people in the US, and there are no FDA-approved therapies for it.

The IPO itself was modest, and the post-debut surge has pushed the stock above the $16.80 to $24.50 range that early analyst reports set. That is the key risk: Vogenx is clinical-stage, with no registrational readout on the calendar until 2027, and mizagliflozin’s gastroparesis and GIP-dependent Cushing’s syndrome programs are earlier still. The company issued 6.3 million shares, giving it a market value of roughly $186 million at the current price. A 127% run on a company with no Phase 3 data leaves little room for error if the EMERGE trial disappoints or the PBH narrative cools.

What to watch next: the Phase 2b EMERGE readout in 2027 and whether avexitide’s FDA submission raises the bar or builds the category. For the catalyst that lit up the PBH space, see the Amylyx avexitide coverage.

Source: Vogenx IPO pricing press release